5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details

臨床試験数 : 95 / 薬物数 : 119 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

47 trials found

diseases per page:

Showing 1 to 10 of 47 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03446807 (ClinicalTrials.gov)	December 2021	20/2/2018	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism	Parkinson Disease;Multiple System Atrophy;Progressive Supranuclear Palsy	Drug: Droxidopa;Drug: Placebo Oral Tablet	Loma Linda University	H. Lundbeck A/S	Not yet recruiting	50 Years	N/A	All	32	Phase 2	United States
2	NCT04993768 (ClinicalTrials.gov)	October 15, 2021	19/7/2021	A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)	A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)	Progressive Supranuclear Palsy	Drug: TPN-101, 100 mg/day;Drug: TPN-101, 200 mg/day;Drug: TPN-101, 400 mg/day;Drug: Placebo	Transposon Therapeutics, Inc.	NULL	Recruiting	41 Years	86 Years	All	40	Phase 2	United States
3	NCT04937530 (ClinicalTrials.gov)	June 23, 2021	16/6/2021	RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY	A Randomized, Double-blind, Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Toler ...	Progressive Supranuclear Palsy	Drug: RT001;Drug: Placebo	Retrotope, Inc.	NULL	Recruiting	40 Years	80 Years	All	40	Phase 2	Germany
4	NCT04539041 (ClinicalTrials.gov)	February 16, 2021	25/8/2020	Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supra ...	A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate th ...	Progressive Supranuclear Palsy (PSP)	Drug: antisense oligonucleotide;Drug: placebo	Novartis Pharmaceuticals	NULL	Recruiting	40 Years	75 Years	All	66	Phase 1	United States;Canada;Germany;United Kingdom
5	NCT04253132 (ClinicalTrials.gov)	January 1, 2021	17/12/2019	Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks	A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ...	Progressive Supranuclear Palsy	Drug: Tolfenamic Acid;Drug: Placebos	NeuroTau, Inc.	The Cleveland Clinic	Not yet recruiting	40 Years	85 Years	All	24	Phase 1/Phase 2	United States
6	NCT04008355 (ClinicalTrials.gov)	June 22, 2020	18/6/2019	A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP	A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess Tolerab ...	Progressive Supranuclear Palsy	Drug: AZP2006 oral solution;Drug: Placebo oral solution	AlzProtect SAS	NULL	Recruiting	40 Years	80 Years	All	36	Phase 2	France
7	NCT04185415 (ClinicalTrials.gov)	December 3, 2019	2/12/2019	A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, ...	A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, ...	Progressive Supranuclear Palsy	Drug: bepranemab;Drug: Placebo	UCB Biopharma SRL	NULL	Completed	40 Years	N/A	All	25	Phase 1	Belgium;Germany;Spain;United Kingdom
8	NCT03924414 (ClinicalTrials.gov)	November 15, 2019	2/4/2019	Trial of Parkinson's And Zoledronic Acid	TOPAZ: Trial of Parkinson's And Zoledronic Acid A Randomized Placebo-controlled Trial of Zoledronic ...	Parkinson Disease;Osteoporosis;Parkinsonism;Parkinson's Disease and Parkinsonism;Atypical Parkinsoni ...	Drug: Zoledronic Acid 5Mg/Bag 100Ml Inj;Other: Placebo	California Pacific Medical Center Research Institute	National Institute on Aging (NIA);University of California, San Francisco;Duke University;University ...	Recruiting	60 Years	N/A	All	3500	Phase 4	United States
9	NCT04184063 (ClinicalTrials.gov)	September 16, 2019	29/7/2019	Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)	A Pilot Exploratory, Randomised, Placebo-controlled, Double Blinded, Cross-over , Phase 2a Study to ...	Progressive Supranuclear Palsy;Multiple System Atrophy	Drug: NBMI;Other: Placebo	EmeraMed	NULL	Completed	40 Years	85 Years	All	20	Phase 2	Slovenia
10	NCT04014387 (ClinicalTrials.gov)	June 2, 2019	11/4/2019	Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)	Treatment of Disturbed Sleep in Progressive Supranuclear Palsy (PSP)	Treatment	Drug: Suvorexant;Drug: Zolpidem;Drug: Placebo oral capsule	University of California, San Francisco	US Department of Veterans Affairs	Recruiting	18 Years	N/A	All	60	Phase 4	United States

First Previous1 2 3 4 5Next Last